Krka Group reported revenue of €1,534 million for the period from January to September 2025, marking a 7% increase compared to the same period last year. Net profit reached €323.7 million, which is a 15% rise year on year. The figures were discussed during a regular meeting of the Krka Supervisory Board, where the interim report for both the Krka Group and Krka, d. d., Novo mesto was reviewed.
Jože Colarič, President of the Management Board and Chief Executive Officer, stated: “The Krka Group continued to record good business results also in the third quarter. We increased our product and service sales by 7% in the first nine months, generating over €1.5 billion. Sales grew across five sales regions, most of our markets, and all product and service groups. We added 17 new products to our product portfolio. Net profit increased by 15% year on year. Based on achieved results, we expect the Krka Group target sales to outstrip the plans and create €2,020 million in product and service sales, and net profit of €383 million.
We presented the updated 2026–2030 Krka Group Development Strategy to the Supervisory Board yesterday. The strategy prioritises uninterrupted supply of medicines and further growth in individual markets and selected therapeutic categories, primarily for treating chronic diseases.
We plan to strengthen and optimise our vertically integrated business model, proven to be an effective strategic guideline and our competitive advantage, as it ensures high standards of product quality, safety, and efficacy. We intend to maintain our focus on maximising the long-term profitability of the products sold. Our strategy aims to deliver on sustainability goals and business targets, reinforcing our commitment to maintaining our economic, social, and environmental responsibility to the environment in which we operate. The revised strategy serves as the underlying structure for the 2026 business plan. We plan product and service sales at €2,132 million and net profit at €405 million.”
The company expects its full-year sales for 2025 will exceed initial projections with anticipated revenues reaching €2,020 million and net profit forecasted at €383 million.
Looking ahead to 2026 under its updated development strategy for 2026–2030 presented to its Supervisory Board this week, Krka aims for further expansion in key therapeutic areas such as chronic disease treatment while focusing on sustainable growth through its vertically integrated operations model.
